Press coverage about Mylan (NASDAQ:MYL) has trended somewhat positive on Thursday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mylan earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.4036788929948 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
MYL has been the subject of several research analyst reports. Deutsche Bank set a $50.00 price objective on Mylan and gave the company a “buy” rating in a research report on Wednesday, January 24th. Mizuho boosted their price objective on Mylan from $45.00 to $51.00 and gave the company a “buy” rating in a research report on Thursday, March 15th. Morgan Stanley set a $50.00 target price on Mylan and gave the company a “buy” rating in a research note on Monday, April 9th. BidaskClub cut Mylan from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 26th. Finally, UBS set a $54.00 target price on Mylan and gave the company a “buy” rating in a research note on Thursday, March 1st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $46.86.
Shares of Mylan traded down $0.30, reaching $39.33, on Thursday, Marketbeat.com reports. 3,249,936 shares of the company were exchanged, compared to its average volume of 4,935,114. Mylan has a one year low of $29.39 and a one year high of $47.82. The stock has a market cap of $20.21 billion, a P/E ratio of 8.63, a P/E/G ratio of 1.27 and a beta of 1.35. The company has a quick ratio of 0.65, a current ratio of 1.06 and a debt-to-equity ratio of 1.03.
Mylan (NASDAQ:MYL) last announced its quarterly earnings data on Wednesday, May 9th. The company reported $0.96 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.99 by ($0.03). Mylan had a return on equity of 18.56% and a net margin of 6.04%. The company had revenue of $2.68 billion for the quarter, compared to the consensus estimate of $2.74 billion. During the same quarter in the prior year, the company earned $0.93 EPS. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. sell-side analysts expect that Mylan will post 5.36 EPS for the current year.
In other news, insider Paul Campbell sold 7,030 shares of the company’s stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $44.01, for a total transaction of $309,390.30. Following the sale, the insider now owns 17,054 shares in the company, valued at approximately $750,546.54. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert J. Coury sold 150,000 shares of the company’s stock in a transaction that occurred on Friday, March 2nd. The stock was sold at an average price of $40.10, for a total value of $6,015,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 269,287 shares of company stock worth $11,034,960. Company insiders own 0.69% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.